Organisation paid for research Program year 2025 Source: CMS Open Payments

Centro de Endocrinologia del Este CSP

Neither a doctor nor a teaching hospital

Research payments

$239,910

22 payments

Through program year 2025, Centro de Endocrinologia del Este CSP is reported as receiving $239,910 in research payments, across 22 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,869 3
2024 Research $20,968 4
2023 Research $3,109 3
2022 Research $670 2
2021 Research $66,478 4
2020 Research $2,777 3
2019 Research $135,039 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly Export S.A. Puerto Rico Branch $198,538 5 payments
  2. Eli Lilly and Company $41,372 17 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $136,061 3 payments
  2. A Phase 2, Parallel, Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Insulin Naive Patients With Type 2 Diabetes Mellitus $61,523 2 payments
  3. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $28,926 2 payments
  4. A Randomized, Phase 3, Double-Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With Or Without Metformin $4,149 3 payments
  5. A Randomized, Phase 3, Open Label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With Or Without Metformin (Surpass 6) $2,487 2 payments
  6. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $1,543 2 payments
  7. A Phase 3 Parallel-Design Open-Label Randomized Controlled Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections $1,262 1 payment
  8. A Study of Orforglipron (Ly3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With Or Without Metformin And/?Or Sglt-2 Inhibitor (Achieve-5) $1,245 2 payments
  9. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $973 1 payment
  10. A Phase 3 Randomized Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine With Or Without Metformin And/Or Sglt-2 Inhibitor $875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record